JBJanina R. Behrens

Janina R. Behrens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janina R. Behrens has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Friedemann Paul

    Max Delbrück Centrum für Molekulare Medizin und Charité – Universitätsmedizin Berlin

    4 shared publications
  • Alexander Ulrich Brandt

    Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

    2 shared publications
  • Heinrich J. Audebert

    Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin

    2 shared publications
  • Judith Bellmann-Strobl

    Experimental and Clinical Research Center, A Cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Germany

    2 shared publications
  • Karen Otte

    Medical Informatics Group, Center of Health Data Science, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

    2 shared publications
  • Malgorzata Kotlarz-Böttcher

    Department of Neurology, University Hospital Greifswald

    2 shared publications

Latest Publications

  • Open Access

    Extending telestroke to broader teleneurology in sparsely populated regions: real-world experience from a German network

    by Maike Kern, Tim Bastian Braemswig, Stephan Kinze, Malgorzata Kotlarz-Böttcher, Heinrich J. Audebert, Janina R. Behrens

    Introduction: Telestroke networks provide established infrastructure for specialist neurological care in rural regions, but their real-world use beyond stroke remains insufficiently characterized. We aimed to describe the diagnostic spectrum of acute teleconsultations within a comprehensive teleneurology network in sparsely populated and structurally underserved regions of Northeast Germany and to explore factors associated with the distribution of diagnoses. Methods: We conducted a retrospective observational analysis of acute teleneurological consultations performed within the ANNOTeM network at 12 continuously participating hospitals between January 2023 and December 2024. Consultations were classified into seven predefined diagnostic categories. Diagnostic distribution was analyzed descriptively; univariable binary and exploratory multinomial logistic regression models were used to examine associations with patient-, hospital-, and regional-level characteristics. Results: Of 4,697 consultations, 4,207 had a single diagnostic category. Suspected stroke accounted for 60.0%, whereas 40.0% concerned non-stroke presentations, reaching 48.3% at individual hospitals (range 30.8–48.3%). More than 70% of non-stroke cases received another neurological diagnosis rather than a non-neurological diagnosis. Median patient age was 70 years. Increasing age was significantly associated with neurological diagnosis (OR per 10 years 1.09, 95% CI 1.04–1.15; p < 0.001) and suspected stroke (OR 1.42, 95% CI 1.38–1.48; p < 0.001). A higher regional proportion of residents aged 60–80 years was significantly associated with neurological diagnosis (OR 1.04, 95% CI 1.00–1.07; p = 0.039). A higher density of neurology-related outpatient specialists was significantly associated with a lower relative likelihood of another neurological diagnosis compared with suspected stroke (OR 0.94, 95% CI 0.89–0.98; p = 0.008). Discussion: Overall, these findings demonstrate that our network, built on an established telestroke infrastructure, is frequently used for comprehensive acute teleneurology in routine clinical care. The substantial non-stroke workload, consisting mostly of neurological diagnoses, together with its associations with demographic structure and specialist availability, highlights the growing relevance of comprehensive teleneurology in aging and underserved regions. Existing telestroke networks may therefore provide a practical platform for bridging geographical and temporal gaps in neurological specialist care beyond stroke.

  • Open Access

    Cost-effectiveness analysis of a telemedicine network for acute neurological care in northeast Germany (ANNOTeM)

    by Janina Behrens, Tobias Kurth, Malgorzata Kotlarz-Böttcher, Anselm Angermaier, Sarah Theen, Rohat Geran, Heinrich J. Audebert

    Background: Expert neurological care in rural areas remains a major challenge and contributes to disparities in outcomes after acute neurological emergencies. To address this gap, the ANNOTeM project established a comprehensive, digitally enabled “hub-and-spoke” telemedicine network connecting academic neurology centers with regional hospitals in northeast Germany, providing 24/7 remote expertise, standardized operating procedures, and digital quality management. Methods: This prospective pre and post implementation study used statutory health insurance claims to compare patient outcomes and costs for acute neurological emergencies across 11 ANNOTeM network hospitals vs. 11 matched non-network hospitals (all hospitals were localized in rural regions). The analysis included all consecutively hospitalized adults with ICD-10 coded acute neurological disorders. The primary clinical endpoint was the composite of 90-day mortality, new need for outpatient or nursing home care. Health economic evaluation included direct medical, non-medical, and indirect costs from the insurer's perspective. Results: Following network implementation, the rate of the primary outcome decreased in ANNOTeM hospitals (33.8% vs. 35.9%; unadjusted absolute difference: −2.1%; adjusted absolute difference: −3.2%; aHR 0.89, 95% CI: 0.79–0.99), with no improvement in control hospitals (40.7% vs. 42.5%; aHR 1.04, 95% CI: 0.85–1.15). Mean 90-day total costs per patient rose modestly from €11,938 to €12,252 (+2.6%, non-significant). Non-network hospitals showed a similar non-significant cost increase. The cost per avoided adverse composite outcome was €14,968 (unadjusted). Conclusion: Implementing a digitally integrated teleneurology network was associated with improved patient outcomes without substantial increases in per-patient costs. These results support the economic sustainability and transformative potential of innovative, network-based telemedicine systems for acute neurological care in underserved, rural regions.


  • Open Access

    Baló’s concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures

    by S. Jarius, C. Würthwein, J. R. Behrens, J. Wanner, J. Haas, F. Paul, B. Wildemann

    Baló’s concentric sclerosis (BCS) is a rare inflammatory demyelinating disorder of the central nervous system characterised by concentric layers of demyelination. It is unclear whether BCS is a variant of multiple sclerosis (MS) or a disease entity in its own right. To compare the cerebrospinal fluid (CSF) features of BCS to those of MS. Retrospective analysis of the CSF profile of all patients with BCS reported in the medical literature between 1980 and 2017. In total, the results of 146 lumbar punctures (LP) in 132 patients were analysed. The most striking finding was a lack of CSF-restricted oligoclonal bands (OCB) in 66% (56/85) of all LP in the total BCS group, in 74% (14/19) in the subgroup of patients with both MRI and histological evidence for BCS, and in 82% (18/22) in the subgroup of patients with highest radiological confidence (high MRI quality, ≥ 3 layers of demyelination). OCB disappeared in 1/2 initially OCB-positive patients. These findings are in stark contrast to MS, in which OCB are present in ≥ 95% of patients and are thought to remain stably detectable over the entire course of disease (p < 0.000001). OCB frequency was low both in ‘historic’ patients (1980–2009; 37%) and in more recent patients (2010–2017; 31%). OCB-positive and OCB-negative patients did not differ significantly with regard to age, sex, disease duration, number of Baló-like lesions on MRI, number of relapses, treatment or final outcome. In accordance with the high rate of OCB negativity, Link’s IgG index was negative in 63% of all tested samples (p < 0.000001 vs. MS). CSF pleocytosis was present in 28% (27/96; p < 0.000001 vs. MS) and elevated CSF total protein levels in 41% (31/76) of samples. OCB and IgG index frequencies in BCS are much more similar to those reported in neuromyelitis optica or myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis than to those in MS. Our findings suggest that in most cases BCS-like lesions denote the presence of a disease entity immunologically distinct from MS. In addition, we provide data on the demographics, clinical course and radiological features of BCS based on the largest cohort analysed to date.


  • Open Access

    Long-Lasting Enhancement of Visual Perception with Repetitive Noninvasive Transcranial Direct Current Stimulation

    by Janina R. Behrens, Antje Kraft, Kerstin Irlbacher, Holger Gerhardt, Manuel C. Olma, Stephan A. Brandt

    Understanding processes performed by an intact visual cortex as the basis for developing methods that enhance or restore visual perception is of great interest to both researchers and medical practitioners. Here, we explore whether contrast sensitivity, a main function of the primary visual cortex (V1), can be improved in healthy subjects by repetitive, noninvasive anodal transcranial direct current stimulation (tDCS). Contrast perception was measured via threshold perimetry directly before and after intervention (tDCS or sham stimulation) on each day over 5 consecutive days (24 subjects, double-blind study). tDCS improved contrast sensitivity from the second day onwards, with significant effects lasting 24 hours. After the last stimulation on day 5, the anodal group showed a significantly greater improvement in contrast perception than baseline and the sham group (23% vs. 5%). We found significant long-term effects in only the central 2–4° of the visual field 4 weeks after the last stimulation. We suspect a combination of two factors contributes to these lasting effects. First, the V1 area that represents the central retina was located closer to the polarization electrode, resulting in higher current density. Second, the central visual field is represented by a larger cortical area relative to the peripheral visual field (cortical magnification). This is the first study showing that tDCS over V1 enhances contrast perception in healthy subjects for several weeks. This study contributes to the investigation of the causal relationship between the external modulation of neuronal membrane potential and behavior (in our case, visual perception). Because the vast majority of human studies only show temporary effects after single tDCS sessions targeting the visual system, our study underpins the potential for lasting effects of repetitive tDCS-induced modulation of neuronal excitability.


  • Open Access

    Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life

    by Theresa Krüger, Janina R. Behrens, Anuschka Grobelny, Karen Otte, Sebastian Mansow-Model, Bastian Kayser, Judith Bellmann-Strobl, Alexander U. Brandt, Friedemann Paul, Tanja Schmitz-Hübsch

    Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods (subjective plus objective) to assess PA reduction in PwMS and to describe the relation of PA to health-related quality of life (hrQoL). PA was objectively measured over a 7-day period in 26 PwMS (EDSS 1.5–6.0) and 30 matched healthy controls (HC) using SenseWear mini® armband (SWAmini) and reported as step count, mean total and activity related energy expenditure (EE) as well as time spent in PA of different intensities. Measures of EE were also derived from self-assessment with IPAQ (International Physical Activity Questionnaire) long version, which additionally yielded information on the context of PA and a classification into subjects’ PA levels. To explore the convergence between both types of assessment, IPAQ categories (low, moderate, high) were related to selected PA parameters from objective assessment using ANOVA. Group differences and associated effect sizes for all PA parameters as well as their relation to clinical and hrQoL measures were determined. Both, SWAmini and IPAQ assessment, captured differences in PA between PwMS and HC. IPAQ categories fit well with common cut-offs for step count (p = 0.002) and mean METs (p = 0.004) to determine PA levels with objective devices. Correlations between specifically matched pairs of IPAQ and SWAmini parameters ranged between r .288 and r .507. Concerning hrQoL, the lower limb mobility subscore was related to four PA measures, while a relation with patients’ report of general contentment was only seen for one. Both methods of assessment seem applicable in PwMS and able to describe reductions in daily PA at group level. Whether they can be used to track individual effects of interventions to enhance PA levels needs further exploration. The relation of PA measures with hrQoL seen with lower limb mobility suggests lower limb function not only as a major target for intervention to increase PA but also as a possible surrogate for PA changes.


  • Open Access

    Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis

    by Andreas Keller, Petra Leidinger, Eckart Meese, Jan Haas, Christina Backes, Ludwig Rasche, Janina R. Behrens, Catherina Pfuhl, Katharina Wakonig, René M. Gieß, et al.

    Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) have a similar clinical phenotype but represent distinct diseases, requiring different therapies. MicroRNAs (miRNAs) are short non-coding RNAs whose expression profiles can serve as diagnostic biomarkers and which may be involved in the pathophysiology of neuroinflammatory diseases. Here, we analyzed miRNA profiles in serum and whole blood of patients with NMOSD and clinically isolated syndrome (CIS)/relapsing-remitting MS (RRMS) as well as healthy controls by next-generation sequencing (NGS). MiRNA expression profiles were determined by NGS in sera of patients with aquaporin-4 antibody-positive NMOSD (n = 20), CIS/RRMS (n = 20), and healthy controls (n = 20) and in whole blood of patients with NMOSD (n = 11), CIS/RRMS (n = 60), and healthy controls (n = 43). Differentially expressed miRNAs were calculated by analysis of variance and t tests. All significance values were corrected for multiple testing. Selected miRNAs were validated in whole blood of patients with NMOSD (n = 18) and CIS/RRMS (n = 19) by quantitative real-time polymerase chain reaction (qRT-PCR). None of 261 miRNAs detected in serum but 178 of 416 miRNAs detected in whole blood showed significantly different expression levels among the three groups. Pairwise comparisons revealed 115 (NMOSD vs. CIS/RRMS), 141 (NMOSD vs. healthy controls), and 44 (CIS/RRMS vs. healthy controls) miRNAs in whole blood with significantly different expression levels. qRT-PCR confirmed different expression levels in whole blood of patients with NMOSD and CIS/RRMS for 9 out of 10 exemplarily chosen miRNAs. In silico enrichment analysis demonstrated an accumulation of altered miRNAs in NMOSD in particular in CD15+ cells (i.e., neutrophils and eosinophils). This study identifies a set of miRNAs in whole blood, which may have the potential to discriminate NMOSD from CIS/RRMS and healthy controls. In contrast, miRNA profiles in serum do not appear to be promising diagnostic biomarkers for NMOSD. Enrichment of altered miRNAs in CD15+ neutrophils and eosinophils, which were previously implicated in the pathophysiology of NMOSD, suggests that miRNAs could be involved in the regulation of these cells in NMOSD.


  • Open Access

    Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test

    by Janina Behrens, Caspar Pfüller, Sebastian Mansow-Model, Karen Otte, Friedemann Paul, Alexander U Brandt

    We investigated the applicability and feasibility of perceptive computing assisted gait analysis in multiple sclerosis (MS) patients using Microsoft Kinect™. To detect the maximum walking speed and the degree of spatial sway, we established a computerized and observer-independent measure, which we named Short Maximum Speed Walk (SMSW), and compared it to established clinical measures of gait disability in MS, namely the Expanded Disability Status Scale (EDSS) and the Timed 25-Foot Walk (T25FW).